Akums Drugs & Pharma Quarterly Results for Trading Insights

In Sept 2025, Akums Drugs & Pharma (AKUMS) reported revenue ₹1,050 Cr and net profit ₹43 Cr. For annual financials, live price and key ratios, visit Akums Drugs & Pharma stock price NSE .

Latest Quarter Net Profit
₹43 Cr
QSept 2025
Quarterly Results

AKUMS Quarterly Results — Revenue, Profit & EPS Highlights

Akums Drugs & Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with AKUMS intrinsic value calculation to assess whether the stock is under or overvalued.

  • Revenue of ₹1,050 Cr in Sept 2025 (-2.9% vs Mar 2025, +0.0% vs Sept 2024)
  • Net Profit of ₹43 Cr in Sept 2025 (-71.3% vs Mar 2025, -35.8% vs Sept 2024)
  • EBITDA of ₹127 Cr in Sept 2025 (+5.8% vs Mar 2025)
  • Operating Margin of 9.0% in Sept 2025 (+0.0pp vs Mar 2025)
  • Earnings Per Share of ₹2.66 in Sept 2025 (-72.4% vs Mar 2025)

Akums Drugs & Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

AKUMS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 1,050 1,081 1,051 1,194 1,050 -2.9% -
Net Profit (₹ Cr) 43 150 65 68 67 - -
EBITDA (₹ Cr) 127 120 156 163 138 - -
EPS (₹) 2.66 9.64 4.15 4.33 4.37 - -
Operating Margin (%) 9.0% 9.0% 13.0% 11.0% 12.0% - -

AKUMS Share Price Trend — 1-Year Movement Across Quarterly Results

Akums Drugs & Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse AKUMS FII DII holdings to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 4.1%
EBITDA Margin 12.1%
Operating Margin 9.0%
ROE (Annual) 5.6%

Balance Sheet Highlights

Total Assets ₹4,113 Cr
Total Equity ₹3,064 Cr
Current Assets ₹2,275 Cr
Current Liabilities ₹156 Cr

Cash Flow Analysis

Operating Cash Flow ₹465 Cr
Investing Cash Flow ₹-548 Cr
Financing Cash Flow ₹73 Cr
Net Cash Flow ₹-10 Cr

Current Market Data

Current Price ₹533.20
Exchange NSE
Last Updated Apr 28, 2026

Revenue Trend (₹ Cr)

Dec 2025 1,194
Jun 2025 1,051
Mar 2025 1,081
Sept 2025 1,050

Net Profit Trend (₹ Cr)

Dec 2025 68
Jun 2025 65
Mar 2025 150
Sept 2025 43

Operating Margin Trend (%)

Dec 2025 11.0%
Jun 2025 13.0%
Mar 2025 9.0%
Sept 2025 9.0%

AKUMS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Akums Drugs & Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹415,924.72 Cr 1747.3 14,875 3,125 +10.8% - 21.0% 134.4
Divis Laboratories
Sept 2025 		₹171,625.44 Cr 6432.5 2,860 689 +7.1% - 24.1% 247.7
Torrent Pharmaceuti…
Sept 2025 		₹139,344.76 Cr 4182.9 3,219 591 +11.3% - 18.4% 238.5
Dr Reddys Laborator…
Sept 2025 		₹109,930.83 Cr 1354.6 9,135 1,337 +1.1% - 14.6% 83.7
Lupin
Sept 2025 		₹104,941.69 Cr 2302.7 6,921 1,485 +23.2% - 21.5% 71.2
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores